COMMUNIQUÉS West-GlobeNewswire

Cellectis to Report First Quarter 2024 Financial Results on May 28, 2024
27/05/2024
NEW YORK, May 27, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell [...]
Cellectis publiera ses résultats financiers du premier trimestre 2024 le 28 mai 2024
27/05/2024
NEW YORK, 27 mai 2024 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), société de biotechnologie de stade clinique qui utilise sa technologie pionnière d’édition du génome TALEN® pour développer [...]
Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC
27/05/2024
Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC Leuven, BELGIUM – May 27, 2024 – 07:00 PM CET (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, today [...]
EssilorLuxottica: Disclosure of Share Capital and Voting Rights Outstanding as of April 30, 2024
27/05/2024
Disclosure of Share Capital and Voting Rights Outstanding as of April 30, 2024 (Pursuant to Article L.233-8 II of the French Commercial Code and articles 221-1 and 223-16 of the General Regulations of the Autorité des [...]
EssilorLuxottica: Nombre total de droits de vote et d’actions composant le capital social au 30 avril 2024
27/05/2024
Nombre total de droits de vote et d’actions composant le capital social au 30 avril 2024 (Conformément à l’article L.233-8 II du Code de Commerce et aux articles 221-1 et 223-16 du Règlement Général de l’AMF) Charenton- [...]
BioSenic S.A. : Positive vote of the majority of creditors in favor of the global restructuring plan of BioSenic covering the years 2024-2032, at the Enterprise Court of Nivelles
27/05/2024
PRESS RELEASE - PRIVILEGED INFORMATION After a recent circular consultation of the creditors, based on XX 83/23 of the Economic Law Code (ELC), the Enterprise Court of Nivelles registers today the positive votes of the [...]
BioSenic S.A. : Vote positif de la majorité des créanciers en faveur du plan global de restructuration de BioSenic couvrant les années 2024-2032, au Tribunal d'Entreprise de Nivelles
27/05/2024
COMMUNIQUE DE PRESSE – INFORMATION PRIVILEGIEE Après une récente consultation circulaire des créanciers, basée sur l'article XX 83/23 du Code de droit économique (CDE), le Tribunal des Entreprises de Nivelles enregistre [...]
Transactions in Connection with Share Buy-back Program
27/05/2024
Company Announcement COPENHAGEN, Denmark; May 27, 2024 – Genmab A/S (Nasdaq: GMAB). On March 15, 2024, Genmab announced the initiation of a share buy-back program to repurchase up to DKK 3.5 billion worth of shares. The [...]
Novo Nordisk A/S - share repurchase programme
27/05/2024
Bagsværd, Denmark, 27 May 2024 – On 6 May 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) [...]
Vaxil Bio Enters Into Letter of Intent With Green Data in Respect of A Proposed Reverse Takeover
27/05/2024
Not for distribution to United States newswire services or for release publication, distribution or dissemination directly, or indirectly, in whole or in part, in or into the United States TORONTO, May 27, 2024 (GLOBE [...]
Helsinn and Angelini Pharma sign a partnership agreement renewal to commercialize AULIN® and MESULID® in Bulgaria, Czech Republic, Hungary, Poland, Romania and Slovak Republic
27/05/2024
Helsinn and Angelini Pharma sign a partnership agreement renewal to commercialize AULIN ® and MESULID ® in Bulgaria, Czech Republic, Hungary, Poland, Romania and Slovak Republic Lugano (Switzerland) and Rome (Italy)– [...]
Samsung Bioepis Announces Oral Presentation on Switching Period Results for SB16, a Proposed Biosimilar to Prolia (Denosumab) at the European Calcified Tissue Society (ECTS) Congress 2024
27/05/2024
Follow-up results from Phase 3 study on SB16: switching period up to Month 18 Study shows SB16 comparable with reference denosumab before and after switching in terms of efficacy, pharmacokinetics, pharmacodynamics, [...]
Press Release: Sarclisa accepted for FDA priority review for the treatment of transplant-ineligible newly diagnosed multiple myeloma
27/05/2024
Sarclisa accepted for FDA priority review for the treatment of transplant-ineligible newly diagnosed multiple myeloma FDA Priority Review granted based on positive results from IMROZ phase 3 study If approved, Sarclisa [...]
Communiqué de presse : La FDA accorde un examen prioritaire au Sarclisa pour le traitement des patients atteints d’un myélome multiple nouvellement diagnostiqué non éligibles à une transplantation
27/05/2024
La FDA accorde un examen prioritaire au Sarclisa pour le traitement des patients atteints d’un myélome multiple nouvellement diagnostiqué non éligibles à une transplantation L’examen prioritaire accordé par la FDA est [...]
Changes to the Roche Enlarged Corporate Executive Committee
27/05/2024
Basel, 27 May 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that James Sabry (1958), Head of Roche Pharma Partnering, will be retiring after fourteen years with the company. James Sabry joined Genentech in [...]
Vera Therapeutics Presents 72-week eGFR Stabilization and Rapid Hematuria Improvement in Phase 2b ORIGIN Study of Atacicept in IgAN at the 61st European Renal Association Congress
25/05/2024
72-week data consistent with disease modification in IgAN, selected as a best-ranked abstract; Rapid and sustained improvements in hematuria over 36 weeks, with resolution in significantly greater percentage of [...]
Novartis atrasentan Phase III data show clinically meaningful proteinuria reduction further advancing company's IgA nephropathy (IgAN) portfolio
25/05/2024
In the ALIGN study, atrasentan, in addition to supportive care with a renin-angiotensin system (RAS) inhibitor, demonstrated a statistically significant 36.1% proteinuria (protein in urine) reduction vs. placebo + [...]
Novartis presents latest Phase III Fabhalta® (iptacopan) data in C3 glomerulopathy (C3G) showing clinically meaningful and statistically significant 35.1% proteinuria reduction vs. placebo
25/05/2024
Secondary endpoint data for estimated glomerular filtration rate (eGFR) showed numerical improvement over 6 months vs. placebo 1 ; additional 6-month open-label data to be presented at a future medical meeting 2,3 [...]
Merus : publication d’un résumé sur l’association pétosemtamab + pembrolizumab dans le traitement de 1re ligne du CETC r/m lors de l’édition 2024 du congrès ASCO®
25/05/2024
- Taux de réponse de 60 % observé auprès de 10 patients évaluables - Profil d’innocuité favorable chez 26 patients recrutés à la date de clôture du résumé, sans aucune observation de chevauchement significatif des [...]

Pages